NT-3

NT-3 Molekülinformation

Englischer Name	Neurotrophin-3	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	2	Target-Alias	Neurotrophin 3，NGF2，NT-3，Neurotrophic factor，HDNF，Nerve growth factor 2，NGF-2，NT3
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Neurotrophin-3
Target-Alias	Neurotrophin 3，NGF2，NT-3，Neurotrophic factor，HDNF，Nerve growth factor 2，NGF-2，NT3
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	2
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

NT-3 Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
Tag Free (2)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
NT3-H5213	Human	HEK293	Human NT-3 Protein, Tag Free, low endotoxin (HPLC verified)				In den Warenkorb legen
NT3-H5215	Human	HEK293	Human NT-3 Protein, premium grade				In den Warenkorb legen

Gesamtmenge2

Produktanfrage

NT-3 Molekülhintergrund

Neurotrophin-3 (NT-3), encoded by the NTF3 gene, is a member of the NGF family of neurotrophic factors (also named neurotrophins). The neurotrophin family is comprised of at least four proteins including NGF, BDNF, NT-3, and NT-4/5. These secreted cytokines are synthesized as prepropeptides that are proteolytically processed to generate the mature proteins. Their functions including supporting the survival and differentiation of existing neurons, encouraging the growth and differentiation of new neurons and synapses, are required in both the central and the peripheral nervous systems. NT-4 signals predominantly through the TrkB receptor tyrosine kinase. NTF3-deficient mice generated by gene targeting display severe movement defects of the limbs. The mature peptide of this protein is identical in all mammals examined including human, pig, rat and mouse.

NT-3 Molekülalias

HDNF,Nerve growth factor 2,NGF-2,Neurotrophic factor,NTF3,NT3.Neurotrophin3

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
scAAV1.tMCK.NTF3		Phase 2 Clinical	Nationwide Children'S Hospital, Sarepta Therapeutics Inc	Charcot-Marie-Tooth Disease	Details
LEVI-04	LEVI-04; p75NTR-Fc	Phase 2 Clinical	Levicept	Arthritis; Joint Diseases; Musculoskeletal Diseases; Osteoarthritis; Osteoarthritis, Knee; Pain; Rheumatic Diseases	Details